-
FBXW7–SPT6–ΔNp63 Axis in Esophageal Cancer
2026-09-20
The reference study identifies SPT6 as a previously unrecognized FBXW7 substrate and shows that coordinated degradation of SPT6 and ΔNp63 suppresses 4-nitroquinoline N-oxide–induced esophageal tumorigenesis. Its genetically defined models and human-tissue analyses position the SPT6–ΔNp63 axis as a context-dependent mechanism and a potential therapeutic entry point in esophageal squamous cell carcinoma.
-
Mubritinib (TAK 165): Metabolic Assay Design
2026-09-19
Mubritinib (TAK 165) is best understood through an assay strategy that separates HER2 activity from mitochondrial complex I inhibition. This article translates metabolic target validation, orthogonal phenotyping, and cross-domain evidence into practical workflows for AML, PEL, and cancer biology research.
-
IR-820 (New Indocyanine Green) Imaging Guide
2026-09-18
IR-820, also known as New Indocyanine Green, is a near-infrared research dye positioned for vascular imaging, tumor localization, and diseased tissue quantification in living-animal studies. Its product specifications define a solid compound with a molecular weight of 849.47 g/mol, while melanoma nanotherapy evidence involving conventional indocyanine green illustrates a related but distinct application boundary.
-
Cy5 maleimide (non-sulfonated): Thiol Labeling
2026-09-18
Cy5 maleimide (non-sulfonated) provides mono-reactive fluorescent labeling of accessible thiol groups, especially cysteine residues, for protein tracking, imaging, and assay development. Its low aqueous solubility requires preparation in DMSO or ethanol, so it is not suitable for direct addition as a dry solid to aqueous biomolecule solutions or for labeling targets without available thiols.
-
EZ Cap™ Human PTEN mRNA (ψUTP) Guide
2026-09-17
EZ Cap™ Human PTEN mRNA (ψUTP) is an in vitro transcribed mRNA reagent encoding human PTEN for mammalian gene-expression studies. Its Cap 1 structure, pseudouridine triphosphate, and poly(A) tail are designed to support mRNA stability enhancement, translation, and reduced RNA-mediated innate immune activation.
-
EdU Imaging Kits (Cy3): S-Phase Workflow
2026-09-17
EdU Imaging Kits (Cy3) translate DNA replication into a bright, antibody-free readout for mesangial-cell biology, developmental kidney research, and controlled proliferation studies. This workflow combines fluorescence microscopy, flow cytometry, and practical controls to distinguish altered S-phase entry from changes in cell number or morphology.
-
Cy5-UTP RNA Labeling for LNP Tracking
2026-09-16
Cy5-UTP enables direct, far-red visualization of RNA made by T7 RNA polymerase, supporting RNA probe synthesis, FISH, arrays, and cargo-tracking studies. This workflow translates a lung-targeted LNP design concept into practical assays while emphasizing controls that distinguish RNA localization from productive mRNA delivery.
-
Cy5 amine (non-sulfonated) Labeling Guide
2026-09-16
Cy5 amine (non-sulfonated) is a primary-amine cyanine reagent for covalent fluorescent labeling of compatible activated biomolecules when a red-emitting dye is required. It must first be dissolved in DMSO or ethanol because it is insoluble in water, so it is unsuitable for direct aqueous addition, diagnostic testing, or medical use.
-
Ziprasidone–GOT1 Reprogramming in Pancreatic Cancer
2026-09-15
The reference study identifies ziprasidone as a non-competitive GOT1 inhibitor that disrupts glutamine metabolism, redox homeostasis, and proliferation in pancreatic ductal adenocarcinoma. Its combined biochemical, metabolomic, genetic, cellular, and xenograft evidence supports GOT1 as a metabolic vulnerability while also defining important limits for translating the findings into therapeutic or redox-assay workflows.
-
mRNA Lipoplexes as Tumour Vaccines: Study Insights
2026-09-15
The reference study optimized PEGylated cationic mRNA lipoplexes prepared by a modified ethanol injection method and evaluated their ability to reduce pulmonary accumulation while preserving antitumour immunity. Its findings connect carrier composition with antibody production, cytotoxic lymphocyte activity, and tumour-growth control, providing a useful framework for assessing systemic mRNA vaccine delivery.
-
BHQ: A Mechanistic Guide to SERCA Calcium Studies
2026-09-14
2,5-di-tert-butylbenzene-1,4-diol (BHQ) is a useful SERCA perturbagen for resolving calcium-store biology. This guide connects assay design, vascular signaling, and the 2025 HSC-mobilization study while emphasizing how to interpret BHQ-induced calcium changes without overclaiming selectivity.
-
Dual-Mode mRNA: From Uptake to Translation
2026-09-14
Translational mRNA programs need to distinguish cellular delivery from productive protein expression. This thought-leadership article examines how Cap1 capping, 5-moUTP modification, Cy5 fluorescence, and firefly luciferase bioluminescence create a state-resolved framework for optimizing delivery systems, with lessons from a recent CRISPR-LNP study in choroidal neovascularization.
-
Cy5-UTP: Mapping Multivalent rRNA Architecture
2026-09-13
Cy5-UTP can turn RNA architecture from an inferred property into a measurable experimental variable. By connecting Cyanine 5-uridine triphosphate labeling with recent findings on 28S rRNA expansion segments and nucleolar organization, this article outlines how translational researchers can design better RNA probe synthesis, imaging, and reconstitution workflows while controlling for labeling-induced artifacts.
-
ARCA Cy5 EGFP mRNA: A Smarter Assay Strategy
2026-09-12
ARCA Cy5 EGFP mRNA (5-moUTP) enables orthogonal measurement of mRNA uptake, intracellular localization, and translation. This article explains how to use its Cy5 and EGFP signals to benchmark emerging delivery systems, including biodegradable polyester LNPs, without confusing particle entry with functional cytosolic expression.
-
Patient-Derived Gastric Cancer Assembloids
2026-09-11
Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine matched tumor organoids with stromal cell subpopulations from the same tumor tissue. The model reproduced tumor-associated transcriptional features and revealed that stromal composition can alter drug sensitivity, supporting more physiologically relevant studies of resistance and personalized treatment.